第三腰椎骨骼肌指数在终末期肝病营养诊断中的应用价值

耿楠; 孔明; 陈煜; 段钟平

doi:10.3969/j.issn.1001-5256.2021.10.050

第三腰椎骨骼肌指数在终末期肝病营养诊断中的应用价值

DOI: 10.3969/j.issn.1001-5256.2021.10.050

首都医科大学附属北京佑安医院肝病中心四科，肝衰竭与人工肝治疗研究北京市重点实验室，北京 100069

基金项目:

国家科技重大专项"艾滋病和病毒性肝炎等重大传染病防治" (2017ZX10203201-005);

国家重点研发计划资助项目 (2017YFA0103000);

北京市医院管理局临床医学发展专项经费资助 (ZYLX201806)

详细信息

通信作者:
段钟平，duan@ccmu.edu.cn

耿楠、孔明对本文贡献相同，同为第一作者。

中图分类号: R575
计量
- 文章访问数: 856
- HTML全文浏览量: 179
- PDF下载量: 110
- 被引次数: 21
出版历程
- 收稿日期: 2021-03-15
- 录用日期: 2021-04-06
- 出版日期: 2021-10-20

Value of L3 skeletal muscle index in nutritional diagnosis of end-stage liver disease

Fourth Department of Liver Disease Center & Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" (2017ZX10203201-005);

National Key R&D Program of China (2017YFA0103000);

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201806)

摘要

摘要: 终末期肝病患者因营养摄入减少、能量消耗增加、禁食适应性受损、肝糖原储备减少、蛋白质消耗增加常导致营养不良。第三腰椎骨骼肌指数(L3-SMI)(第三腰椎横断面肌肉的面积/身高平方)是反映终末期肝病营养不良的重要指标，具有客观性强、受水钠潴留影响小、可重复性好等优点。回顾了L3-SMI在肝硬化、肝衰竭、肝癌和接受肝移植患者营养不良诊断的相关研究。分析表明，L3-SMI可系统评估终末期肝病患者营养状况和营养干预的效果，有望成为终末期肝病营养诊断的重要手段。
- 终末期肝病 /
- 营养不良 /
- 身体成分 /
- 诊断 /
- 预后
Abstract: Patients with end-stage liver disease often have malnutrition caused by reduced nutrient intake, increased energy consumption, impaired fasting adaptability, reduced liver glycogen reserve, and increased protein consumption. L3 skeletal muscle index (L3-SMI) (skeletal muscle cross-sectional area at the level of L3/square of height) is an important indicator for evaluating malnutrition in end-stage liver disease, with the advantages of strong objectivity, little influence by water-sodium retention, and good repeatability. This article reviews the application of L3-SMI in the nutritional diagnosis of liver cirrhosis, liver failure, liver cancer, and liver transplantation. The analysis shows that L3-SMI can effectively evaluate nutritional status and the effect of nutritional intervention in patients with end-stage liver disease, and therefore, it is expected to become an important method for nutritional diagnosis in end-stage liver disease.
- End Stage Liver Disease /
- Malnutrition /
- Body Composition /
- Diagnosis /
- Prognosis

HTML全文

参考文献(26)

[1]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010. 中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
[2]	PLAUTH M, BERNAL W, DASARATHY S, et al. ESPEN guideline on clinical nutrition in liver disease[J]. Clin Nutr, 2019, 38(2): 485-521. DOI: 10.1016/j.clnu.2018.12.022.
[3]	European Association for the Study of the Liver. EASL Clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
[4]	SINCLAIR M, GOW PJ, GROSSMANN M, et al. Review article: Sarcopenia in cirrhosis—aetiology, implications and potential therapeutic interventions[J]. Aliment Pharmacol Ther, 2016, 43(7): 765-777. DOI: 10.1111/apt.13549.
[5]	KAZEMI-BAJESTANI SMR, MAZURAK VC, BARACOS V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes[J]. Seminars in cell & developmental biology, 2016, 54: 2-10. DOI: 10.1016/j.semcdb.2015.09.001.
[6]	LINDQVIST C, BRISMAR TB, MAJEED A, et al. Assessment of muscle mass depletion in chronic liver disease: Dual-energy x-ray absorptiometry compared with computed tomography[J]. Nutrition, 2019, 61: 93-98. DOI: 10.1016/j.nut.2018.10.031.
[7]	LI TZ, KONG M, CHEN Y. Association between end-stage liver disease and sarcopenia[J]. J Clin Hepatol, 2020, 36(3): 693-696. DOI: 10.3969/j.issn.1001-5256.2020.03.050. 李侗曾, 孔明, 陈煜. 终末期肝病与肌少症的关系[J]. 临床肝胆病杂志, 2020, 36(3): 693-696. DOI:10. 3969/j.issn.1001-5256.2020.03.050.
[8]	REN X, HAO S, YANG C, et al. Alterations of intestinal microbiota in liver cirrhosis with muscle wasting[J]. Nutrition, 2020, 83: 111081. DOI: 10.1016/j.nut.2020.111081.
[9]	EBADI M, BHANJI RA, DUNICHAND-HOEDL AR, et al. Sarcopenia severity based on computed tomography image analysis in patients with cirrhosis[J]. Nutrients, 2020, 12(11): 3463. DOI: 10.3390/nu12113463.
[10]	NAMBA M, HIRAMATSU A, AIKATA H, et al. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis[J]. J Gastroenterol, 2020, 55(2): 217-226. DOI: 10.1007/s00535-019-01623-4.
[11]	BENMASSAOUD A, ROCCARINA D, ARICO F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites[J]. Am J Gastroenterol, 2020, 115(11): 1911-1914. DOI: 10.14309/ajg.0000000000000959.
[12]	TATEYAMA M, NAOE H, TANAKA M, et al. Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: A case control study[J]. BMC Gastroenterol, 2020, 20(1): 371. DOI: 10.1186/s12876-020-01501-x.
[13]	NARDELLI S, LATTANZI B, MERLI M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology, 2019, 70(5): 1704-1713. DOI: 10.1002/hep.30692.
[14]	GIOIA S, MERLI M, NARDELLI S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS[J]. Liver Int, 2019, 39(5): 871-877. DOI: 10.1111/liv.14050.
[15]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[16]	LI L, CHEN Y. The recent research progress in nutritional assessment and intervention treatment of liver failure in patients[J]. Chin J Hepatol, 2017, 25(7): 548-552. DOI: 10.3760/cma.j.issn.1007-3418.2017.07.017. 李璐, 陈煜. 肝衰竭患者的营养评估及营养干预研究进展[J]. 中华肝脏病杂志, 2017, 25(7): 548-552. DOI: 10.3760/cma.j.issn.1007-3418.2017.07.017.
[17]	LI TZ, KONG M, SONG WY, et al. Relationship between skeletal muscle index of third lumbar vertebrae and clinical characteristics in patients with acute on chronic liver failure[J]. J Practical Hepatol, 2020, 23(4): 467-470. DOI: 10.3969/j.issn.1672-5069.2020.04.004. 李侗曾, 孔明, 宋文艳, 等. 慢加急性肝衰竭患者第三腰椎骨骼肌指数与临床指标的关系[J]. 实用肝脏病杂志, 2020, 23(4): 467-470. DOI: 10.3969/j.issn.1672-5069.2020.04.004.
[18]	SHACHAR SS, WILLIAMS GR, MUSS HB, et al. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review[J]. Eur J Cancer, 2016, 57: 58-67. DOI: 10.1016/j.ejca.2015.12.030.
[19]	YABUSAKI N, FUJII T, YAMADA S, et al. Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection[J]. Int J Surg, 2016, 30: 136-142. DOI: 10.1016/j.ijsu.2016.04.049.
[20]	BERARDI G, ANTONELLI G, COLASANTI M, et al. Association of sarcopenia and body composition with short-term outcomes after liver resection for malignant tumors[J]. JAMA surgery, 2020, 155(11): e203336. DOI: 10.1001/jamasurg.2020.3336.
[21]	KOBAYASHI T, KAWAI H, NAKANO O, et al. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies[J]. BMC Cancer, 2018, 18(1): 756. DOI: 10.1186/s12885-018-4673-2.
[22]	UOJIMA H, CHUMA M, TANAKA Y, et al. Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib[J]. Liver Cancer, 2020, 9(2): 193-206. DOI: 10.1159/000504604.
[23]	UCHIKAWA S, KAWAOKA T, NAMBA M, et al. Skeletal muscle loss during tyrosine kinase inhibitor treatment for advanced hepatocellular carcinoma patients[J]. Liver Cancer, 2020, 9(2): 148-155. DOI: 10.1159/000503829.
[24]	MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6(7): e102. DOI: 10.1038/ctg.2015.31.
[25]	GOLSE N, BUCUR PO, CIACIO O, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation[J]. Liver Transpl, 2017, 23(2): 143-154. DOI: 10.1002/lt.24671.
[26]	KAMO N, KAIDO T, MIYACHI Y, et al. Preoperative abnormal body composition is closely related to bacteremia after living donor liver transplantation[J]. Nutrition, 2020, 77: 110798. DOI: 10.1016/j.nut.2020.110798.

施引文献

期刊类型引用(17)

1.	李斌华，陈小勇，李雷. 加强门静脉高压症的临床管理，促进失代偿性肝硬化再代偿. 肝脏. 2025(02): 262-265 . 百度学术
2.	杨晶艳，刘丽萍，陈梅春，周双红. 慢性乙型肝炎患者服药依从性的影响因素分析. 健康研究. 2024(02): 167-171+176 . 百度学术
3.	李斌华，谢峰，闫雪华，陈小勇，李雷，王文青. 综合医院MDT模式下肝硬化门静脉高压症患者全病程管理的探讨. 临床医学研究与实践. 2024(36): 182-185 . 百度学术
4.	罗发燕，陈铁霞，罗平平，诸伟红. 慢性乙型肝炎患者服药依从性调查. 预防医学. 2023(11): 966-969+974 . 百度学术
5.	蔡冬梅，胡婷婷. 网络互动式健康教育对中青年乙型肝炎患者疾病认知及治疗依从性的影响. 中国医药导报. 2022(04): 166-169 . 百度学术
6.	吕卉. 慢性病毒性肝炎患者治疗依从性的相关影响因素分析. 当代护士(上旬刊). 2022(01): 58-60 . 百度学术
7.	宋如梅，魏芹，李晶，薛群. “3-PR”参与式健康教育对慢性乙肝患者疾病认知及健康行为的影响. 海军医学杂志. 2022(01): 109-112 . 百度学术
8.	王玉美，李雪，范琪琪，王爱敏. 青岛慢性乙型肝炎患者抗病毒治疗服药依从性现状及影响因素分析. 社区医学杂志. 2022(04): 228-232 . 百度学术
9.	邓娜娜，周美芳. "5个时刻法"用药宣教应用于慢性乙型肝炎抗病毒治疗中的效果. 国际护理学杂志. 2022(06): 1104-1107 . 百度学术
10.	沈璐，周翠梅，张静，薛继华，李惠萍. 慢性乙型肝炎患者抗病毒治疗知信行量表的编制及信效度检验. 中国健康教育. 2021(03): 217-221 . 百度学术
11.	李振洁. 延伸护理服务在慢性乙型肝炎患者院外护理中的应用. 河南医学研究. 2021(07): 1329-1331 . 百度学术
12.	杨玲. 影响慢性乙型肝炎患者服药依从性相关危险因素及其干预措施分析. 内蒙古医学杂志. 2021(07): 836-838 . 百度学术
13.	王蕾，王丹，李汝珂，李长安，赵巍峰. “五个时刻法”延续用药指导在慢性乙型肝炎长期抗病毒治疗中的应用价值. 新乡医学院学报. 2021(06): 526-530 . 百度学术
14.	钟丽梅，唐霏林，杨柳琴，陆艳珍，黄桂敏，黄艳. 慢性乙型肝炎患者抗病毒治疗期间自我停药状况及影响因素. 河北医药. 2021(17): 2614-2617 . 百度学术
15.	田晓英. 医护药一体化模式对慢性乙型肝炎病人用药依从性及负性情绪的影响. 全科护理. 2021(34): 4857-4859 . 百度学术
16.	林顺伟，周舒冬，郜艳晖，李粤平，贾卫东，梁颖芳，杨翌. 慢性乙型肝炎患者抗病毒治疗的依从性分析. 临床肝胆病杂志. 2020(03): 532-535 . 本站查看
17.	王贵菊，鲁荣华. 1022例慢性乙型肝炎病毒感染者现状及影响因素. 中国卫生工程学. 2020(03): 336-338 . 百度学术